Trial reportThe pharmacogenomics journal2013
The PPAR alpha gene is associated with triglyceride, low-density cholesterol and inflammation marker response to fenofibrate intervention: the GOLDN study.
Trial report in The pharmacogenomics journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 46 citations in OpenAlex.
- Trial
- The association between LRP-1 variants and chylomicron uptake after a high fat meal.Nutrition, metabolism, and cardiovascular diseases : NMCD · 2013Trial
- Review
- Precision Medicine in Cardiovascular Disease Prevention: Clinical Validation of Multi-Ancestry Polygenic Risk Scores in a U.S. Cohort.Nutrients · 2025Article
- Improvement of Cardiovascular Risk Factors by Genistein Supplementation: A Systematic Review and Meta-Analysis in Diverse Population-Based RCTs.Journal of nutrition and metabolism · 2025Review
- Investigating the impact of extreme weather events and related indicators on cardiometabolic multimorbidity.Archives of public health = Archives belges de sante publique · 2024Article
- Peroxisome Proliferator-Activated Receptor-α (International journal of molecular sciences · 2022Article
- Bilirubin as an indicator of cardiometabolic health: a cross-sectional analysis in the UK Biobank.Cardiovascular diabetology · 2022Article
- CES2 sustains HNF4α expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop.Molecular metabolism · 2022Article
- N-Acetyl Cysteine, Selenium, and Ascorbic Acid Rescue Diabetic Cardiac Hypertrophy via Mitochondrial-Associated Redox Regulators.Molecules (Basel, Switzerland) · 2021Article
- An exome-wide sequencing study of lipid response to high-fat meal and fenofibrate in Caucasians from the GOLDN cohort.Journal of lipid research · 2018Article
- Article
- DNA methylation as a marker of response in rheumatoid arthritis.Pharmacogenomics · 2017Review
- An epigenome-wide association study of inflammatory response to fenofibrate in the Genetics of Lipid Lowering Drugs and Diet Network.Pharmacogenomics · 2017Article
- Pioglitazone treatment following spinal cord injury maintains acute mitochondrial integrity and increases chronic tissue sparing and functional recovery.Experimental neurology · 2017Article
- Modulation of PPAR Expression and Activity in Response to Polyphenolic Compounds in High Fat Diets.International journal of molecular sciences · 2016Review
- Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine?Current atherosclerosis reports · 2016Review
- Identification of Haplotype Tag Single-Nucleotide Polymorphisms within the PPAR Family Genes and Their Clinical Relevance in Patients with Major Trauma.International journal of environmental research and public health · 2016Article
- Differential Roles of Peroxisome Proliferator-Activated Receptor-α and Receptor-γ on Renal Crystal Formation in Hyperoxaluric Rodents.PPAR research · 2016Article
- Lipid changes due to fenofibrate treatment are not associated with changes in DNA methylation patterns in the GOLDN study.Frontiers in genetics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
As a peroxisome proliferator-activated receptor alpha (PPARα) agonist, fenofibrate favorably modulates dyslipidemia and inflammation markers, which are associated with cardiovascular risk. To determine whether variation in the PPARα receptor gene was associated with lipid and inflammatory marker response, we conducted a 3-week trial of fenofibrate in 861 men and women. Mixed linear models that controlled for age and sex, as well as family pedigree and study center, were constructed using single-nucleotide polymorphisms (SNPs) in the PPARα gene as predictors and changes in fasting triglycerides (TGs), cholesterol and inflammatory markers as outcomes. Significant associations with low-density cholesterol and interleukin-2 (P<0.001) responses to fenofibrate were found. Although there were suggestive associations with tumor necrosis factor-alpha and TG responses (P<0.05), these did not survive the correction for multiple testing. We conclude that variants in the PPARα gene may contribute to future pharmacogenomic paradigms seeking to predict fenofibrate responders from both an anti-dyslipidemic and anti-inflammatory perspective.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.